HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.
about
How to select the best available related or unrelated donor of hematopoietic stem cells?Haploidentical Stem Cell Transplantation in Adult Haematological MalignanciesNonmyeloablative allogeneic hematopoietic cell transplantationReview on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic MalignanciesHaploidentical Transplantation in Children with Acute Leukemia: The Unresolved IssuesNovel insights in the management of sickle cell disease in childhoodMyeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant CyclophosphamideHaploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic DisordersNovel Techniques for Ex Vivo Expansion of Cord Blood: Clinical TrialsModern approaches to HLA-haploidentical blood or marrow transplantationHematopoietic stem cell transplantation in sickle cell disease: patient selection and special considerationsProgress toward curing HIV infection with hematopoietic cell transplantationAdvances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disordersMilestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current DevelopmentsImmunity to Infections after Haploidentical Hematopoietic Stem Cell TransplantationHaematopoietic cell transplants in Latin AmericaAlternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaUpdate of hematopoietic cell transplantation for sickle cell diseaseHaploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular TherapyNational Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report.Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.Cord blood collection and banking from a population with highly diverse geographic origins increase HLA diversity in the registry and do not lower the proportion of validated cord blood units: experience of the Marseille Cord Blood Bank.Role of major histocompatibility complex variation in graft-versus-host disease after hematopoietic cell transplantation.Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysisPost-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantationThe effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemiaCord-Blood Transplantation in Patients with Minimal Residual DiseaseMismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignanciesHematopoietic stem cell transplantation-50 years of evolution and future perspectives.Acute myeloid leukemia: 2014 update on risk-stratification and management.Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewalAnti-HLA antibody testing in hematology patients.Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation.Race, Ethnicity and Ancestry in Unrelated Transplant Matching for the National Marrow Donor Program: A Comparison of Multiple Forms of Self-Identification with Genetics.High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.Banking or Bankrupting: Strategies for Sustaining the Economic Future of Public Cord Blood Banks.Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.Better allele-level matching improves transplant-related mortality after double cord blood transplantation.
P2860
Q26744109-55CAA537-E60B-4D0F-8A46-D3CC46DA2FD0Q26745527-46ADEA4D-5565-47D0-83C1-E221B59D5E2DQ26748780-82E47AE5-E3DE-4840-B938-BDC75DF75576Q26749120-1299F52D-195E-4444-AE75-DC40B5F509E5Q26750671-08FEB358-1E14-42A8-BBCD-B2E3038DC960Q26767015-354827F7-AAD3-460A-B077-9B8EF2AF8C06Q26767438-4C6571E5-2687-4649-BF5E-A751FC2DE380Q26767501-5750FAAF-C227-402E-9679-6FD466907A1CQ26772216-9EF373EE-67B5-42BE-A218-6F432D1B3C6BQ26797506-8A211AB7-0696-4092-A8CC-35BB99CCEE90Q26800236-D61FA836-8076-40E0-8117-78312888122FQ26801269-91A03321-588E-44E5-A6B5-405FF2263DB5Q27022561-FBA20905-BB55-485A-A6EE-55479DE576A4Q28067102-2486261B-66A5-485D-A380-7CA8A5BCC94AQ28079606-745FF9DD-273D-48E2-9611-DB171D0305E2Q28080094-4AD692F2-8D3B-402B-A0FB-90919BF2EB11Q28080943-A720CD06-E0F1-4AC9-B9BF-D825E5315136Q28083007-E82AEB18-9204-4E12-B04F-AABFDE6EF123Q28085397-59851892-6501-47AB-9E4F-A57AD39526E6Q30245682-78937447-4973-4DA2-BF2A-3B8C132EC1FDQ30252339-38498CD0-A8F0-45E6-9983-B9CE33D2A691Q30252975-91780DAE-3BA6-430E-98E9-DF433E7AAAD4Q33457123-D0B39C79-F02D-47F5-8B5D-DE0D7A852339Q33642419-45B6EC27-1BC5-4358-A878-E9CF22EB7426Q33689153-4B653208-73ED-4FF6-A9EE-12183035A141Q33764825-BB2A08D2-9C13-4A03-89AE-5B0644CDAAACQ33816017-B35D6FF9-D85C-4633-8936-F0FC42090BF8Q33911314-5FD97BAD-63F5-4674-B892-EB71F24F9E96Q34175568-1B7A653F-C142-4930-9F98-8A44B12F5AECQ34463419-858B9CEE-D1EA-4752-9DFE-DB752ADE0CCAQ34665691-A716A9C4-AE11-489B-AB6B-3A3655703A80Q34749292-7771224F-4719-41FE-9069-52C5D268E052Q35263804-F236DEF6-C2B8-47DF-A1BE-9261D537FC56Q35457908-CD501ADE-674F-4A77-B2C6-756C862D0812Q35583385-B3546A47-EB71-4660-8844-DF2F0D26F864Q35749922-5E170164-6596-4F21-A08B-3DAE7AA5E09DQ35847466-6AB95893-5CD4-44A9-A29E-6551BFC53251Q35856939-3F91AB3A-CE23-4410-A361-CE26B49DB06CQ35976578-1631D750-4526-43BE-86BC-0A8FA0E99CC7Q36115699-85BD63CD-86CA-40A9-9387-B054D061F824
P2860
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.
@en
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.
@nl
type
label
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.
@en
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.
@nl
prefLabel
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.
@en
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.
@nl
P2093
P2860
P356
P1476
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.
@en
P2093
Dennis Confer
Eric Williams
J Douglas Rizzo
John Freeman
Loren Gragert
Mary Eapen
Mary Horowitz
Robert Baitty
Robert Hartzman
Stephen Spellman
P2860
P304
P356
10.1056/NEJMSA1311707
P407
P577
2014-07-01T00:00:00Z